Latest Panic Disorder News

Page 1 of 2
Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.
Ada Torres
Ada Torres
19 Mar 2026
Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.
Ada Torres
Ada Torres
4 Mar 2026
Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.
Ada Torres
Ada Torres
17 Feb 2026
InhaleRx Limited has progressed its clinical trials for three drug candidates targeting cancer pain, panic disorder, and treatment-resistant depression, while securing additional funding and preparing for a company rebrand.
Ada Torres
Ada Torres
29 Jan 2026
InhaleRx Limited has completed the final tranche of its share placement, raising $600,000 to support its clinical-stage drug development programs targeting pain and mental health.
Ada Torres
Ada Torres
9 Jan 2026
InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.
Ada Torres
Ada Torres
23 Dec 2025
InhaleRx advances its clinical pipeline with a new oral treatment for resistant depression and plans a strategic rebrand to Nexalis Therapeutics, signaling a broader focus beyond inhaled therapies.
Ada Torres
Ada Torres
10 Dec 2025
InhaleRx Limited has secured $427,500 from an initial tranche of its $1 million capital raise, issuing 17.1 million shares to support its inhaled therapies targeting pain and mental health conditions.
Ada Torres
Ada Torres
9 Dec 2025
InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.
Ada Torres
Ada Torres
31 Oct 2025
InhaleRx has secured ethics approval to begin a Phase 1 clinical trial of IRX-616a, a synthetic cannabidiol inhaler aimed at providing fast relief for panic disorder. The fully funded study will assess safety and pharmacokinetics in healthy volunteers.
Ada Torres
Ada Torres
28 Aug 2025
InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.
Ada Torres
Ada Torres
25 Aug 2025
InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.
Ada Torres
Ada Torres
22 July 2025